153 related articles for article (PubMed ID: 34229078)
1. A randomized dose-escalation study on the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of a novel recombinant human albumin in healthy subjects.
Li C; Xiang W; Wu M; Zhang H; Cheng J; Yang T; Mai J; Chi X; Gao X; Ding Y; Niu J
Eur J Pharm Sci; 2021 Oct; 165():105923. PubMed ID: 34229078
[TBL] [Abstract][Full Text] [Related]
2. Phase I comparability of recombinant human albumin and human serum albumin.
Bosse D; Praus M; Kiessling P; Nyman L; Andresen C; Waters J; Schindel F
J Clin Pharmacol; 2005 Jan; 45(1):57-67. PubMed ID: 15601806
[TBL] [Abstract][Full Text] [Related]
3. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WBP216, a novel IL-6 monoclonal antibody, in patients with rheumatoid arthritis: A phase Ia randomized placebo-controlled study.
Leng X; Tang X; Hu P; Guan X; Li Q; Huang C; Zhang Q; Chen R; Zeng X
Front Immunol; 2022; 13():1110992. PubMed ID: 36926529
[TBL] [Abstract][Full Text] [Related]
5. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Novel Recombination Human Nerve Growth Factor in Healthy Chinese Subjects.
Shen Q; Zhang M; Jin Y; Di X; Liu R; Wang Z
CNS Drugs; 2023 Mar; 37(3):231-242. PubMed ID: 36811740
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study.
Xu J; Zhang H; Chen H; Zhu X; Jia H; Xu Z; Huo D; Zhang H; Li C; Ding Y
Ann Med; 2023; 55(2):2264850. PubMed ID: 38071661
[No Abstract] [Full Text] [Related]
7. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis.
Zhang L; Zhang W; Xu Y; Dong L; Sun Y; Jia Y; Li Z; Chen B; Hou J; Zhang J
Adv Ther; 2024 Jun; ():. PubMed ID: 38833140
[TBL] [Abstract][Full Text] [Related]
8. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
Neelakantan S; Oemar B; Johnson K; Rath N; Salganik M; Berman G; Pelletier K; Cox L; Page K; Messing D; Tarabar S
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):307-316. PubMed ID: 33352008
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, pharmacokinetics and neutrophil elastase inhibitory effects of Sivelestat: A randomized, double-blind, placebo-controlled single- and multiple-dose escalation study in Chinese healthy subjects.
Li K; Dong L; Gao S; Zhang J; Feng Y; Gu L; Yang J; Liu X; Wang Y; Mao Z; Jiang D; Xia Z; Zhang G; Tang J; Ma P; Zhang W
Eur J Pharm Sci; 2024 Apr; 195():106723. PubMed ID: 38336251
[TBL] [Abstract][Full Text] [Related]
10. M-M-R(®)II manufactured using recombinant human albumin (rHA) and M-M-R(®)II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children.
Wiedmann RT; Reisinger KS; Hartzel J; Malacaman E; Senders SD; Giacoletti KE; Shaw E; Kuter BJ; Schödel F; Musey LK
Vaccine; 2015 Apr; 33(18):2132-40. PubMed ID: 25796337
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers.
Kenney RT; Cini JK; Dexter S; DaFonseca M; Bingham J; Kuan I; Chawla SP; Polasek TM; Lickliter J; Ryan PJ
Front Immunol; 2024; 15():1362775. PubMed ID: 38487528
[TBL] [Abstract][Full Text] [Related]
12. First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects.
Banfield C; Rudin D; Bhattacharya I; Goteti K; Li G; Hassan-Zahraee M; Brown LS; Hung KE; Pawlak S; Lepsy C
Br J Clin Pharmacol; 2020 Apr; 86(4):812-824. PubMed ID: 31758576
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers.
Hu Y; Zhang H; Li X; Mai J; Yang L; Yan J; Li Y; Sun J; Xu W; He S; Li J; Wu M
Expert Opin Investig Drugs; 2022 Sep; 31(9):977-985. PubMed ID: 34633260
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety, and tolerability of TQC3564, a novel CRTh2 receptor antagonist: report of the first-in-human single- and multiple-dose escalation trials in healthy Chinese subjects.
Li X; Li Q; Ji T; Zhang H; Liu J; Wu M; Chen H; Lou J; Liu C; Xu Z; Ding Y
Expert Opin Investig Drugs; 2022 Jul; 31(7):729-736. PubMed ID: 35574691
[TBL] [Abstract][Full Text] [Related]
15. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults.
Chen G; Li N; Dai X; Tu S; Shen Z; Wu K; Jin T; Wu J; Peng C; Sheng G; Zhu M; Tang L; Li L
Infect Dis Ther; 2023 Feb; 12(2):663-675. PubMed ID: 36697937
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial.
Liu C; Dong W; Xia L; Lv J; Jiang D; Wang Q; Wang M; Wu M; Miao J; Tao T; Wang D; Zheng L; Su S; Liu L; Fang Y
Int Immunopharmacol; 2021 Feb; 91():107263. PubMed ID: 33383447
[TBL] [Abstract][Full Text] [Related]
17. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers.
Yang H; Merica E; Chen Y; Cohen M; Goldwater R; Kosinski PA; Kung C; Yuan ZJ; Silverman L; Goldwasser M; Silver BA; Agresta S; Barbier AJ
Clin Pharmacol Drug Dev; 2019 Feb; 8(2):246-259. PubMed ID: 30091852
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blinded, placebo-controlled phase I study of the pharmacokinetics, pharmacodynamics, and safety of KL130008, a novel oral JAK inhibitor, in healthy subjects.
Li N; Du S; Wang Y; Zhu X; Shu S; Men Y; He M; Fang F; Wang Y; Gong Y; Chen J; Gu L; Cheng Y; He Q; Lu H; Niu Y; Xu Y; Feng P
Eur J Pharm Sci; 2022 Sep; 176():106257. PubMed ID: 35820629
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects: A phase 1, single-centre, randomized, double-blind, dose escalation study.
Chen GL; Liu Y; Gao XF; Wu KQ; Yang YK; Chen Y; Peng CG; Jin TH; Huang YB; Zhang YW; Su J; Jiang Q; Guo T; Zhao J; Peng XN; Peng JY; Li SX; Sun YL; Zhang HM; Fu YL; Luo D; Ma Y; Shen ZW; Zhang YT; Shou ZF
Diabetes Obes Metab; 2024 Apr; 26(4):1395-1406. PubMed ID: 38287130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
